Listed Companies
Latest Results
Annual / Interim Reports
Announcements
Press Releases
Company Presentations
Upcoming Events
Corporate Governance
Prospectuses / Circulars
Register with Companies
Stock Quotes
IPO Information
ADR / OTCQX Search
NEW on irasia.com
FREE Email Alerts
Latest Results
Annual / Interim Reports
Announcements
Press Releases
Company Presentations
Upcoming Events
Corporate Governance
Prospectuses / Circulars
Register with Companies
Stock Quotes
IPO Information
ADR / OTCQX Search
NEW on irasia.com
FREE Email Alerts
Neuren Pharmaceuticals Limited
Press Releases
You will need the Adobe Acrobat Reader 7.0 to view the PDF.
If you do not have any of the above, please download "Acrobat Reader".
| Neuren Engages Burrill & Company to Progress Out-licensing Opportunities (in PDF) | |
| Neuren Successfully Raises $1.6 Million Through Share Purchase Plan (in PDF) | |
| Neuren Research Shows Cancer Regression in Preclinical Model (in PDF) | |
| Neuren's Third Lead Drug Candidate, NNZ-2591, Proves Effective at Reversing Memory Loss (in PDF) | |
| Positive Preclinical Results Show Fat Reduction Capability for Neuren's Compound NNZ-3006 (in PDF) | |
| US Army to Conduct Phase 2 Trial of Glypromate® to Reduce Brain Injury from Cardiac Arrest (in PDF) | |
| Favourable Phase 2a Pharmacokinetic and Safety Data for Glypromate® Confirmed (in PDF) | |
| Neuren Presents Phase 2 Clinical Trial Strategy for NNZ-2566 (in PDF) | |
| Neuren Selects New Compound Targeted for the Oral Treatment of Parkinson's and Related Neurological Diseases (in PDF) | |
| Neuren Appoints Chief Operating Officer (in PDF) | |
| NRP Collaboration: Research on Nerve Protection Compounds Published in Science Journal (in PDF) | |
| US Army Presents New Neuren Research Results at International Neuroscience Meeting (in PDF) | |
| Neuren Granted US Patent for NNZ-2566 (in PDF) | |
| Neuren and US Army Continued Success in Traumatic Brain Injury Program and now File Joint Patent (in PDF) | |
| Neuren Reports Successful Phase 2 Results (in PDF) | |
| Preclinical Results for Oral Administration of NNZ-2566 Opens up Significant New Market Opportunities (in PDF) | |
| Neuren's Second Lead Compound to Commence Phase 1 Trial (in PDF) | |
| Neuren and Metabolic Report Promising Animal Efficacy Data in Collaborative Project (in PDF) | |
| 2007 Press Releases |
| © Copyright 1996-2009 irasia.com Ltd. All rights reserved. |
|
DISCLAIMER: irasia.com Ltd makes no guarantee as to the accuracy or completeness of any
information provided on this website. Under no circumstances shall irasia.com Ltd be liable
for damages resulting from the use of the information provided on this website.
TRADEMARK & COPYRIGHT: All intellectual property rights subsisting in the contents of this website belong to irasia.com Ltd or have been lawfully licensed to irasia.com Ltd for use on this website. All rights under applicable laws are hereby reserved. Reproduction of this website in whole or in part without the express written permission of irasia.com Ltd is strictly prohibited. TERMS OF USE: Please read the Terms of Use governing the use of our website. |